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Abstract
End-stage renal disease (ESRD) patients are vulnerable to Mycobacterium tuberculosis (MTB) infection, but the magnitude of the risk is
uncertain. In addition, there is no reliable information on the MTB infection rate of patients undergoing different types of renal replace-
ment therapy (RRT). We used the Taiwan National Health Insurance Research Database to conduct a 9-year nationwide longitudinal
study. Among 49 983 ESRD patients who received three renal replacement modalities, there were 562 cases of MTB infection, corre-
sponding to an incidence rate of 3.0 per 1000 patient-years. The risk of MTB infection relative to the general population was 4.5. Multi-
variate Cox regression analysis indicated that the independent risk factors for MTB infection in ESRD patients are old age (hazard ratio
(HR) 1.17 per 10 years, p <0.001), male gender (HR 1.37, p <0.001), silicosis (HR 5.82, p <0.001), and chronic obstructive pulmonary
disease (HR 1.68, p 0.012). Hyperlipidaemia (HR 0.71, p <0.001) and hypertension (HR 0.81, p 0.05) are associated with a lower infec-
tion rate. There was no effect of RRT modality on MTB infection rate.
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Introduction
Mycobacterium tuberculosis (MTB) infection is the deadliest
infectious disease worldwide, and is responsible for 1.7 mil-
lion deaths per year [1]. Although antimicrobial treatment
for MTB infection was developed more than 50 years ago,
the numbers of MTB cases and deaths continue to increase.
Risk factors for MTB infection are often considered to result
from impaired host immunity or increased exposure to infec-
tion. Age [2], male gender [3], malnutrition [4,5], human
immunodeﬁciency virus (HIV) infection [6], silicosis [7,8], dia-
betes mellitus (DM) [9,10], glucocorticoids [11], receipt of
transplants [12–14], malignancy [15], low socio-economic
status, substance abuse [16] and renal insufﬁciency [17,18]
are known risk factors for MTB infection. Previous studies
indicated that dialysis patients have a 6.9-fold to 52.5-fold
higher risk of MTB infection than the general population
[17]. Most of these previous studies were cross-sectional
single-centre studies that considered only small numbers of
patients, and this is presumably the reason for the wide
range in estimated relative risk (RR).
Patients with end-stage renal disease (ESRD) are treated
with renal replacement therapy (RRT): haemodialysis (HD),
peritoneal dialysis (PD), or kidney transplantation. Each of
these therapies has the potential to increase the probability
of MTB infection. In particular, long-term use of immunosup-
pressant agents by transplant recipients may increase the risk
of infection, long-term attendance at hospital three times a
week may increase the MTB transmission rate among HD
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patients, and peritoneal infection may occur during PD.
However, no previous studies have rigorously examined the
infection rates of patients given different RRT modalities.
Knowledge of the risk of MTB infection following different
RRT modalities is clearly very important, especially in MTB-
epidemic areas. Taiwan has the highest ESRD incidence
worldwide, and is also an MTB-epidemic area.
In the current study, we performed a longitudinal cohort
study in Taiwan to evaluate the MTB infection rate among
ESRD patients. We used the National Health Insurance
Research Database (NHIRD) [19] to evaluate the RR of
MTB infection in ESRD patients, and compared the hazard
ratios for different RRT modalities.
Methods
Data source
This study used data from the NHIRD of Taiwan. In 1995,
universal health insurance was initiated in Taiwan, and this
covers 99% of the population of 23 million people [20]. In
1999, the Bureau of National Health Insurance began to
release all patient data in electronic form under the NHIRD
project [19]. Various extracted datasets are available to
researchers, and hundreds of published papers have used the
NHIRD as the basis for their studies. The NHIRD consists
of de-identiﬁed secondary data released to the public for
research purposes, so the present study was exempt from
full review by the Internal Review Board. In this study, we
excerpted data from a specially ordered dataset that includes
all claim information from patients under the registry of cata-
strophic illness from January 1996 to December 2006. In Tai-
wan, patients with ESRD who need long-term RRT can apply
for catastrophic illness registration cards from the Bureau of
National Health Insurance, so that co-payments are not
required for treatment.
Study design
In the current cohort study, all incident ESRD patients in
Taiwan from 1 January 1998 to 31 December 2004 were
identiﬁed from the catastrophic illness dataset. Age, gender,
RRT modality, comorbid diseases and the socio-economic
status of patients were retrieved from the database. Each
patient was followed from the initiation of RRT to the diag-
nosis of MTB infection, death, withdrawal from the original
RRT, or 31 December 2006. For patients who switched dial-
ysis modality or had kidney transplantation during the study
period, the two RRT periods were analysed separately.
For comparison of the incidence of MTB infection of our
ESRD patients and that of the general population, a longitudinal
health insurance dataset of 1 000 000 beneﬁciaries (randomly
sampled from the original NHIRD) was used as a control group.
The NHIRD published a dataset entitled the Longitudinal Health
Insurance Database (LHID) in 2005. The LHID-2005 contains
the entire original claim data of 1 000 000 beneﬁciaries who
enrolled in 2005, randomly sampled from the 2005 Registry for
Beneﬁciaries (ID) of the NHIRD. Registration data of all
beneﬁciaries of the National Health Insurance programme from
1 January to 31 December 2005 were drawn for random
sampling. There were no signiﬁcant differences in the age and
gender distribution between patients in the LHID-2005 and
those in the original NHIRD [19].
Deﬁnition of RTTs, MTB infection and comorbidity
PD patients are those with catastrophic illness registration
cards for ESRD and insurance claims for PD dialysate. HD
patients are those with catastrophic illness registration cards
for ESRD and insurance claims for HD treatment for more
than 3 months. Kidney transplant recipients are those with
catastrophic illness registration cards for kidney transplanta-
tion (V42.0) and insurance claims for immunosuppressant
agents for more than 3 months. In Taiwan, MTB infection is
a legal infectious disease, and the anti-MTB drugs are con-
trolled by a central government health institute. When a
doctor diagnoses an incident MTB patient and prescribes
anti-tuberculosis (TB) drugs, he or she needs to declare the
case to the Taiwan CDC within 1 week. Because it takes
2 months to obtain the TB culture report in clinical practice,
we deﬁned an MTB-positive patient as one who had an ICD-
9 code (010–018) in at least three ambulatory visits and
insurance claims for anti-TB drugs (isoniazid, rifampicin, rifa-
mycin, rifabutin, pyrazinamide, or ethambutol) for more than
90 days. To validate this deﬁnition, we use the same criteria
in a randomized sample of 1 million, and compared the MTB
infection incidence rate with the Taiwan CDC annual report.
Hypertension, diabetes and hyperlipidaemia were deﬁned by
ICD-9 codes and insurance claims for medication for more
than 90 days per year. HIV infection (ICD-9 code 042), sili-
cosis (ICD-9 codes 501–504), chronic obstructive pulmonary
disease (COPD) (ICD-9 codes 403, 416, 491–493, 495–495,
508, 515, 516, and 518), connective tissue disease (ICD-9
codes 710, 712, 714, 715, 716, 719, and 728) and malignancy
(ICD-9 codes 140–239) were deﬁned by disease codes in at
least three ambulatory visits. The monthly salary of beneﬁcia-
ries was used to indicate economic status.
Statistical analysis
Normally distributed continuous data are expressed as
means ± standard deviations. Numerical data with non-normal
distributions are expressed as medians and interquartile
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ranges. For comparison of parameters between different dial-
ysis modalities, the chi-square test was used for categorical
variables, and ANOVA and the Mann–Whitney U-test were
used for parametric and non-parametric continuous variables,
respectively. The incidence of MTB infection was calculated
by the Kaplan–Meier method, and compared by use of the
log-rank test. Multivariate Cox proportional hazard regres-
sion was performed with backward elimination to analyse
independent risk factors for MTB infection. Risk factors with
p-values <0.1 in univariate Cox analysis were entered into
the multivariate analysis. All probabilities were two-tailed. A
p-value <0.05 was considered to be signiﬁcant.
Results
Basic characteristics of the study population
Fig. 1 illustrates the patient selection ﬂow. During the 7-year
enrolment period, there were 51 443 new cases of ESRD.
After exclusion of patients with coding errors, those who
received RRT for <30 days, those who were <20 years in
age, those with a history of MTB infection before dialysis and
those with age coding errors (seven subjects’ birthday are
coded as 1800/1/1, or age >120 years), we used the records
of 49 983 patients (186 793 patient-year follow-up period)
for analysis.
Table 1 shows the distribution of gender, comorbid dis-
eases, RRT modality and other characteristics. During the 7-
year study period, there were slight increases in the annual
number of new ESRD cases, mean patient age, and cases of
DM, hypertension, and hyperlipidaemia. Table 2 shows the
baseline characteristics of patients stratiﬁed by RRT modality.
Our cohort had 43 495 HD patients (87.0%), 4139 PD
patients (8.3%), and 2249 kidney transplantion patients
(4.7%). HD patients were the oldest, followed by PD
patients, and then kidney transplantion patients (ANOVA,
p <0.001). The PD group had the highest percentage of
females (p <0.001). The transplantation group had the lowest
rate of DM and the highest economic status (p <0.001).
Comparison of MTB infection in the general population and
ESRD patients
With use of the same criteria for diagnosis, the MTB infec-
tion incidence rate in LHID-2005 was 0.65/1000 patient-
years, which is comparable to the 0.67/1000 patient-years
that was reported by the Taiwan Centres for Disease [21].
In our ESRD cohort, 562 patients had MTB infections during
the study period, corresponding to an incidence rate of 3.0/
1000 patient-years. Thus, the RR of MTB infection for our
ESRD patients is 4.5.
Independent predictors of MTB infection in ESRD patients
During the study period, we identiﬁed MTB infection in 562
patients (499 HD patients, 44 PD patients, and 19 kidney
transplantion patients). Univariate Cox regression analysis
indicated that nine risk factors were signiﬁcantly associated
with MTB infection rate (Table 3). In particular, old age, male
gender, low socio-economic status, COPD, silicosis and
development of ESRD before the year 2001 were associated
with an increased MTB infection rate. In contrast, hyperten-
sion, hyperlipidaemia and kidney transplantation (Fig. 2) were
associated with a lower rate of MTB infection. The Kaplan–
Meier plots for each risk factor for MTB infection are
illustrated in Fig. 2.
Multivariate Cox regression analysis indicated that the
following variables were independent risk factors for
MTB infection: old age, male gender, COPD, silicosis, and
From 1998 to 2004
51 443 incident ESRD
patients
373 patients were
under age 20 years
51 070 patients
624 patients had MTB
infection before RRT
50 446 patients
56 patients had MTB infection
within 30 days after RRT
50 390  patients
400 patients had undergone
RRT for less than 30 days
49 990 patients
7 patients with coding error
49 983 patients were analysed
FIG. 1. Patient selection ﬂow chart. ESRD, end-stage renal disease;
MTB, Mycobacterium tuberculosis; RRT, renal replacement therapy.
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development of ESRD before the year 2001. Hyperlipidaemia
and hypertension were signiﬁcant protective factors against
MTB infection.
Discussion
Over the past decade, the Taiwan government has initiated
numerous programmes for prevention of MTB infection,
including the three-phase 5-year plan, the Directly Observed
Treatment Short-course (DOTS) plan, the DOTS-Plus, and
the Mobilization Plan for Halving TB Incidence in 10 Years
[21]. In fact, the incidence rate of MTB infection in Taiwan
has gradually declined over the past decade [22], but MTB
infection is still the most lethal, notiﬁable infectious disease.
Among all notiﬁable infectious diseases, MTB infection has
the greatest number of conﬁrmed cases per year, with more
than 15 000 new infections per year. ESRD patients are vul-
nerable to MTB infection, but previous studies have reported
very different RR rates [23–26], mainly because of the small
sizes of these studies. An exception is the cross-sectional
study conducted by Chou et al. [27], which examined Taiwan
CDC MTB registration data and indicated an annual MTB
infection rate of 24 533 Taiwanese HD patients of 0.5 per
1000 patients in 2001. The other studies only examined 7–
38 MTB infection cases from single centres [17]. Thus, the
present study is valuable because of the large number of
cases and the long follow-up period. The NHIRD contains all
medical claim data for Taiwan, allowing a nationwide longitu-
dinal study.
In agreement with previous studies of general populations,
we identiﬁed old age, male gender, silicosis and COPD as
risk factors for MTB infection in ESRD patients. Malnutrition
can lead to immune system dysregulation, and is a well-
known risk factor for MTB infection [4]. In the current
study, we were unable to measure nutritional parameters,
such as body mass index and serum albumin, but we found
that hyperlipidaemia and hypertension were protective fac-
tors in ESRD patients. Hypertension is common in ESRD
patients, unless the patient has heart failure or insufﬁcient
effective blood volume. In fact, low blood pressure and low
cholesterol are often associated with unfavourable outcomes
in ESRD patients [28,29]. Thus, we believe that hyperlipida-
emia and hypertension are indicators of nutritional status in
ESRD patients. Diabetes increases the risk of MTB infection
TABLE 1. Patient characteristics stra-
tiﬁedbycalendaryear
Characteristics 1998 1999 2000 2001 2002 2003 2004 Overall
New ESRD case, no. 6442 6326 6905 7183 7594 7691 7842 49 983
Male gender (%) 47.1 46.6 46.3 46.7 47.4 47.5 48.1 47.1
Mean age (years) 57.7 58.9 59.4 59.3 60.2 60.6 61.4 59.7
Diabetes (%) 40.9 40.3 42.5 43.2 44.9 42.6 44.0 43.8
Hypertension (%) 79.8 78.8 82.8 85.2 87.1 88.1 88.6 83.6
Hyperlipidaemia (%) 30.1 34.0 37.8 39.8 42.0 45.3 47.2 39.9
Haemodialysis (%) 86.1 87.3 87.3 86.3 87.3 87.1 87.5 87.0
Patients in cohort, no. 6442 12 560 18 371 23 751 29 012 33 894 38 461
ESRD, end-stage renal disease.
TABLE 2. Baseline patient characteristics stratiﬁed by renal
replacement therapy (RRT) modality
RRT modality
HD
N = 43 495
PD
N = 4139
Transplant
N = 2349 p
Demographic data
Age (years), mean ± SD 61.2 ± 13.5 53.7 ± 15.1 43.9 ± 13.1 <0.001
Male gender, % (no.) 47.7 (20 731) 39.2 (1624) 51.5 (1200) <0.001
Monthly Ssalary ($US),
mean ± SD
339 ± 429 458 ± 592 765 ± 721 <0.001
Follow-up days (IQR) 1190
(702–1284)
1230
(770–1868)
2031
(1453–2648)
<0.001
Comorbid disease, % (no.)
Diabetes 45.6 (19 849) 33.9 (1405) 27.7 (651) <0.001
Hypertension 82.9 (36 046) 88.4 (3659) 89.1 (2092) <0.001
Hyperlipidaemia 37.4 (16 272) 58.5 (2422) 52.8 (1241) <0.001
COPD 3.1 (1336) 2.9 (120) 0.8 (19) <0.001
Silicosis 0.11 (50) 0.02 (1) 0.04 (1) 0.143
Malignancy 4.7 (2033) 3.2 (133) 1.7 (40) <0.001
Connective tissue
disease
1.3 (583) 3.5 (145) 3.4 (79) <0.001
Medication, % (no.)
Systemic steroids >12
months
8.0 (3499) 12.1 (502) 87.4 (2052) <0.001
COPD, chronic obstructive pulmonary disease; HD, haemodialysis; IQR, inter-
quartile range; PD, peritoneal dialysis; SD, standard deviation.
TABLE 3. Cox regression analysis for Mycobacterium tuber-
culosis infection risk factors in end-stage renal disease
(ESRD) patients
Parameters
Univariate Multivariate
HR p 95% CI HR p 95% CI
Male gender 1.39 <0.001 1.18–1.65 1.37 <0.001 1.16–1.62
Age (per 10 years) 1.17 <0.001 1.10–1.24 1.17 <0.001 1.10–1.24
ESRD after year 2001 0.52 <0.001 0.44–0.61 0.53 <0.001 0.45–0.63
RRT modality 0.033
Haemodialysis (as
reference)
1.00 1.000 1.00–1.00
Peritoneal dialysis 0.90 0.502 0.66–1.22
Kidney transplantation 0.55 0.011 0.35–0.87
Diabetes 0.87 0.107 0.73–1.03
Hypertension 0.71 0.001 0.58–0.87 0.81 0.050 0.66–1.00
Hyperlipidaemia 0.62 <0.001 0.52–0.75 0.71 <0.001 0.59–0.86
Silicosis 7.32 <0.001 2.74–19.5 5.82 <0.001 2.17–15.6
Steroid use 1.14 0.264 0.90–1.44
COPD 1.76 0.006 1.18–2.63 1.68 0.012 1.12–2.51
Malignancy 1.18 0.224 0.91–1.53
Connective tissue disease 1.29 0.357 0.75–2.24
Monthly salary >$US800 0.71 0.032 0.52–0.97
COPD, chronic obstructive pulmonary disease; HR, hazard ratio; RRT, renal
replacement therapy.
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in the general population; however, the odds ratio is modest.
A large-scale study that compared 500 000 diabetes patients
and 500 000 non-diabetes subjects indicated that the odds
ratio of MTB infection was 1.12 [30]. In our analysis, diabetes
was not a risk factor for MTB infection in ESRD patients. It
is possible that ESRD was such a strong risk factor for MTB
infection that it diminished the impact of other risk factors
with modest odds ratios.
For patients with ESRD, kidney transplantation is consid-
ered the best RRT modality in terms of survival and life quality.
In the current study, we found that kidney transplantation was
associated with a lower MTB infection rate than PD or HD
(Fig. 2), but the transplantation group was also 20 years youn-
ger and had better socio-economic status. After multivariate
adjustment, we found that kidney transplantation was no
longer associated with a lower MTB infection rate.
Since HIV was discovered in the 1980s, the MTB infection
rate has increased worldwide, especially in Africa [31].
According to the WHO annual report of 2009, 15% of MTB
patients were HIV-positive, one-third of MTB-related deaths
were related to concomitant HIV infection, and MTB con-
tributed to 26% of the estimated deaths resulting from HIV
infection [1]. In contrast to Western and African countries,
the HIV infection rate among MTB patients in Taiwan was
only 0.6% in 2007 [22]. In the current study, we only identi-
ﬁed eight patients with HIV infection (all in the HD group),
but none of them developed MTB infection during the obser-
vation period. Thus, HIV infection was not considered in our
data analysis.
The current study had several limitations. First, because of
the retrospective nature of the study, we did not use the
standard procedure for diagnosis of MTB infection (acid-fast
stain and culturing). Instead, we diagnosed MTB infection if a
patient had taken anti-MTB medication for more than
3 months. It is likely that some patients with MTB infections
did not submit claims for medication, or died before
3 months of treatment. Second, it has been reported that
half of the MTB infections of ESRD patients are extrapulmo-
nary, especially among PD patients [32,33]. We were unable
to study this issue, because these data were not available in
the NHIRD. Third, some possibly important risk factors,
such as smoking, nutritional status, intravenous drug abuse,
and occupational exposure, are also not available in the
NHIRD.
In conclusion, the results of this nationwide longitudinal
study indicate that the incidence rate of MTB infection is 3.0/
1000 patient-years for Taiwanese ESRD patients. As com-
pared with the general population, the RR of MTB infection
for ESRD patients is 4.5. The independent risk factors for
MTB infection in ESRD patients are older age, male gender,
malnutrition, silicosis, and COPD. RRT modality had no
affect on the MTB infection rate.
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